HHS release says gene therapy will be made available to Medicaid beneficiaries with sickle cell

A recorded message released by the U.S. Department of Health and Human Services said an initiative will expand access to gene therapy for Americans on Medicaid with sickle cell disease.

Robert F. Kennedy Jr., who appears in the recording released by the U.S. Department of Health and Human Services, said the program "will provide life changing gene therapy to Americans who have sickle cell and [is] expanding access to transformative therapies." He described the agreement behind the program as "an extraordinary negotiation" that, he said, "makes low cost sickle cell treatments that actually cure sickle cell available to all Americans on Medicaid." The recording was produced by the U.S. Department of Health and Human Services.

The announcement included remarks from Janelle Stevenson, identified in the recording as a participant in one of the clinical trials. Stevenson said, "I received life changing gene therapy, which transformed my life with sickle cell disease to now living a life free of pain, free of crises, thriving in my life instead of just trying to survive my life with sickle cell disease." The recording did not specify the therapy used, the manufacturer, the negotiated price, or the timeline for states to implement access.

The speaker in the recording also asserted broader public‑policy benefits, saying a "one‑time cure upfront saves the taxpayers millions and millions of dollars," but the recording did not provide supporting cost estimates, actuarial analyses or citations to fiscal studies. The recording named no federal rule, statute, contract number or specific program details explaining how states would operationalize coverage through Medicaid or how payments to manufacturers would be structured.

The recording referenced public figures but did not include statements from federal health officials, state Medicaid directors, or named manufacturers. It did not record a Q&A or provide documents with implementation steps, funding sources, or legal citations. The U.S. Department of Health and Human Services is listed as the producer of the recording.

The announcement is presented as a national initiative aimed at Medicaid beneficiaries with sickle cell disease. The recording contains claims about clinical benefit and cost savings attributed to participants and the speaker; the recording itself does not provide independent verification of those claims, details on which gene therapy products are covered, or an implementation schedule for states.